Healthcare
Theraclion S.A.(TCLIF)
Live Price
Offline$0.532
+0.00% today
1Y Change
+312841.18%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- $20.00M
- Revenue Growth
- +42.8%
- EPS Growth
- +22.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theraclion S.A. (TCLIF) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.53 and up 312841.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +42.8%, EPS growth of +22.0%, a dividend yield of 0.0%. What stands out right now is revenue +42.8%, EPS +22.0%, free cash flow 0.0% with operating margin -424.4% and ROIC -49.8%. Valuation already assumes a fairly strong business story at price/sales 19.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TCLIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+42.8% vs +7.6% peer median
Operating Margin
Below sector median
-424.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +42.8% and EPS at +22.0%, with operating margin around -424.4%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCLIF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TCLIF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TCLIF and SPY.
Company Overview
Theraclion S.A.
Other OTC
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient's skin and optimizes the image quality. The company was founded in 2004 and is based in Malakoff, France.
- Leadership
- Martin Deterre
- IPO Date
- Apr 22, 2019
- Employees
- 28
- Street Address
- 102 Rue Etienne Dolet
- Mailing
- Malakoff, 92240
- Region
- Malakoff, FR
- Reporting Currency
- USD
- Investor Line
- 33 1 55 48 90 70
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 19.9
- Price/Book
- —
Growth
- Revenue
- +42.8%
- EPS
- +22.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- -528.2%
- Operating Margin
- -424.4%
- Net Margin
- -479.8%
- ROE
- 222.0%
- ROIC
- -49.8%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 2.21
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.